Oncimmune (LON:ONC) Shares Up 11.9% – Time to Buy?

Shares of Oncimmune Holdings plc (LON:ONC) rose 11.9% during mid-day trading on Thursday . The company traded as high as GBX 2.74 ($0.03) and last traded at GBX 2.49 ($0.03). Approximately 59,545 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 610,544 shares. The stock had previously closed at GBX 2.22 ($0.03).

Oncimmune Stock Performance

The stock has a market cap of £1.76 million, a price-to-earnings ratio of 0.17 and a beta of 1.19. The company has a debt-to-equity ratio of -412.06, a current ratio of 1.14 and a quick ratio of 0.63. The firm has a fifty day moving average of GBX 10.25 and a 200 day moving average of GBX 14.19.

Oncimmune (LON:ONC) last issued its earnings results on Monday, February 10th. The company reported GBX (4.72) (($0.06)) earnings per share (EPS) for the quarter. Oncimmune had a negative return on equity of 2,277.74% and a net margin of 581.63%.

Oncimmune Company Profile

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.